title: RESOLUTION OF NONINFECTIOUS UVEITIC CYSTOID MACULAR EDEMA WITH TOPICAL DIFLUPREDNATE.
abstract: OBJECTIVE
  To evaluate the short-term safety and efficacy of topical difluprednate (0.05%) for the treatment of noninfectious uveitic cystoid macular edema.
  
  
  METHODS
  Twenty-seven patients (35 eyes) undergoing treatment with difluprednate 4 times daily for 3 weeks for noninfectious uveitic cystoid macular edema were reviewed for visual acuity, intraocular pressure, optical coherence tomography, and fluorescein angiography results. A mixed model analysis was fit with each measure as the outcome, visit as the primary predictor, and patient and eye as random effects.
  
  
  RESULTS
  Mean central foveal thickness decreased by 117 μm (P < 0.001) at 30 ± 15 days, 124 μm (P < 0.001) at 60 ± 15 days, and 152 μm (P < 0.001) at 180 ± 30 days. Complete resolution of intraretinal fluid was observed in 15 of 34 (44%) eyes at 30 ± 15 days, 11 of 21 (52%) eyes at 60 ± 15 days, and 9 of 12 (75%) eyes at 180 ± 30 days. Improvement in fluorescein leakage was noted in 7 of 8 eyes (88%). Visual acuity improved by a mean of 5 letters (P = 0.001) at 30 ± 15 days, 5.5 letters (P = 0.007) at 60 ± 15 days, and 7 letters (P = 0.032) at 180 ± 30 days. Mean increase in intraocular pressure was 1.48 mmHg at 30 ± 15 days (P = 0.080), 1.92 mmHg at 60 ± 15 days (P = 0.110), and 6.18 mmHg (P = 0.001) at 180 ± 30 days.
  
  
  CONCLUSIONS
  Topical difluprednate is a well-tolerated and effective treatment for noninfectious uveitic cystoid macular edema with decreased central foveal thickness, mild improvement in visual acuity, and elevation of intraocular pressure observed in a few patients.
authors.affiliation: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Feiler
authors.forename: Sunil K
authors.initials: SK
authors.lastname: Srivastava
authors.forename: Francesco
authors.initials: F
authors.lastname: Pichi
authors.forename: James
authors.initials: J
authors.lastname: Bena
authors.forename: Careen Y
authors.initials: CY
authors.lastname: Lowder
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D005260:Female; D005451:Fluorescein Angiography; D005477:Fluprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007429:Intraocular Pressure; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D017063:Outcome Assessment, Health Care / Q000379:methods; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014605:Uveitis / Q000188:drug therapy*; D014792:Visual Acuity
chemical_list: D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D005477:Fluprednisolone; C015808:difluprednate